Metraipolis › archive › dc_f37acabb2b0d
BMS-641988 — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/BMS-641988
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T17:27:25.049Z
- SHA-256 of the archived text
210a389df6b353c881750c8ca51489f8a352fd10d512d3c78df90982c63fe1be- Stable URL of this page
https://metraipolis.com/documento/dc_f37acabb2b0d
How to cite
BMS-641988 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/BMS-641988 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_f37acabb2b0d (Metraipolis archive dc_f37acabb2b0d, sha256 210a389df6b353c881750c8ca51489f8a352fd10d512d3c78df90982c63fe1be)
BibTeX
@misc{dcf37acabb2b0d,
title = {BMS-641988 — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/BMS-641988},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_f37acabb2b0d; sha256 210a389df6b353c881750c8ca51489f8a352fd10d512d3c78df90982c63fe1be},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/BMS-641988. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
BMS-641988 is a nonsteroidal antiandrogen which was developed by Bristol-Myers Squibb for the treatment of prostate cancer but was never marketed. It acts as a potent competitive antagonist of the androgen receptor (AR) (Ki = 10 nM; IC50Tooltip half-maximal inhibitory concentration = 56 nM). The drug was found to have 20-fold higher affinity for the AR than bicalutamide in MDA-MB-453 cells, and showed 3- to 7-fold the antiandrogenic activity of bicalutamide in vitro. It may have some weak partial agonist activity at the androgen receptor. BMS-641988 is transformed by CYP3A4 into BMS-570511, and this metabolite is then reduced to BMS-501949 by cytosolic reductases. All three compounds show similar antiandrogenic activity. In addition to its antiandrogenic activity, BMS-641988 shows activity as a negative allosteric modulator of the GABAA receptor, and can produce seizures in animals at sufficiently high doses. It also shows some drug-induced QT prolongation. BMS-641988 reached phase I clinical trials prior to the discontinuation of its development. The clinical development of BMS-641988 was terminated due to the occurrence of a seizure in a patient during a phase I study. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «BMS-641988» — https://en.wikipedia.org/wiki/BMS-641988 Wikidata Q27166776: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q27166776 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/BMS-641988?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1370573400, consultata il 2026-11-10T17:24:35.857Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 83d6efdf06cc08ccc9273974e84b3ca03c40a6ffc451c725ba6c6feddd9398e9